FMR LLC Sells Shares of Beam Therapeutics Inc.
FMR LLC sold 33,372 shares of Beam Therapeutics, valued at over $1.17 million.
Key Points
- FMR LLC sold 33,372 shares of Beam Therapeutics on June 25, valued at approximately $1.17 million.
- Beam Therapeutics' stock traded at $34.81 on Monday, with a market cap of about $3.58 billion.
- Analysts from Bernstein and Citigroup maintain a 'buy' rating with price targets of $39 and $68, respectively.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
FMR LLC recently sold 33,372 shares of Beam Therapeutics Inc. (NasdaqGS: BEAM), a move valued at around $1.17 million. This transaction took place on June 25, with the shares sold at an average price of $35.12 each.
Other Institutional Activity in Beam Therapeutics
FMR LLC increased its stake in Beam Therapeutics by 543,061 shares, bringing its total holdings to 12,452,199 shares, valued at about $296.7 million, reflecting a 4.6% increase. Meanwhile, ARK Investment Management LLC reduced its holdings by 333,756 shares, ending with 12,133,433 shares worth approximately $289.1 million, marking a 2.7% decrease. Farallon Capital Management LLC added 71,585 shares to its position, holding 10,134,696 shares valued at $241.5 million, a slight 0.7% increase. BlackRock, Inc. also added 37,387 shares, with a total of 8,487,569 shares valued at $202.3 million, representing a 0.4% increase. State Street Corp significantly increased its position by 470,736 shares, totaling 5,699,265 shares worth $135.8 million, a 9% increase. Vanguard Portfolio Management LLC opened a new position with 4,570,797 shares valued at $108.9 million.
Beam Therapeutics Inc. Stock Up 19.2%
On Monday, shares of Beam Therapeutics traded around $34.81. The company has a market cap of approximately $3.58 billion. While it currently isn't profitable, its forward P/E ratio is -7.34. The stock's 52-week range is between $15.60 and $36.88, with a 50-day moving average of $30.69 and a 200-day moving average of $27.36. Beam Therapeutics has a beta of 2.198, indicating higher volatility compared to the market. The company's current ratio is 16.99, and its quick ratio is 16.25, showing strong short-term liquidity.
$BEAM stock price
Daily closing prices, year to date. Not investment advice.
Recent Earnings
Beam Therapeutics reported revenue of $164 million, with a growth rate of 3.25%. However, the company posted a net margin of -40.23% and a return on equity of -5.77%. The next earnings report is expected on August 4, 2026.
Insider Buying and Selling at Beam Therapeutics Inc.
FMR LLC sold 33,372 shares on June 25 at an average price of $35.12, and an additional 251,488 shares on June 26 at $35.26. President Giuseppe Ciaramella bought 35,505 shares on June 17 at an average price of $0.96, and sold the same amount later that day. Insiders Kathleen Walsh and Mark Fishman also bought 19,676 shares each on June 3 at no cost.
Analysts Set New Price Targets
On May 13, 2026, Bernstein maintained a "buy" rating on Beam Therapeutics with a price target of $39. Citigroup, on March 26, kept its "buy" rating with a target of $68. The consensus among 15 analysts is a "strong buy," with a mean target price of $51.07.
About Beam Therapeutics Inc.
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts. It focuses on developing precision genetic medicines for serious diseases. The company's pipeline includes treatments for sickle cell disease and various liver-targeting therapies. Beam Therapeutics collaborates with Pfizer and Verve Therapeutics to advance its research and development efforts. The company was founded in 2017 and is led by CEO John M. Evans.
Bottom Line
FMR LLC's recent sale of Beam Therapeutics shares highlights ongoing insider activity. Investors often track such moves for potential insights, although 13F filings and insider transactions are backward-looking and may not reflect current positions. Beam Therapeutics remains a notable player in the biotech sector, with analyst optimism suggesting potential growth.
Get Beam Therapeutics Inc. alerts
New 13F filings, insider trades, and analyst moves on $BEAM, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.